416 related articles for article (PubMed ID: 35365585)
21. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
[TBL] [Abstract][Full Text] [Related]
22. The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
Krittikarux S; Wudhikarn K; Tangnuntachai N; Assanasen T; Sukswai N; Asawapanumas T; Chanswangphuwana C
Leuk Lymphoma; 2020 Dec; 61(14):3395-3403. PubMed ID: 32820659
[TBL] [Abstract][Full Text] [Related]
23. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
24. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
Georgiou K; Chen L; Berglund M; Ren W; de Miranda NF; Lisboa S; Fangazio M; Zhu S; Hou Y; Wu K; Fang W; Wang X; Meng B; Zhang L; Zeng Y; Bhagat G; Nordenskjöld M; Sundström C; Enblad G; Dalla-Favera R; Zhang H; Teixeira MR; Pasqualucci L; Peng R; Pan-Hammarström Q
Blood; 2016 Jun; 127(24):3026-34. PubMed ID: 27030389
[TBL] [Abstract][Full Text] [Related]
25. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract][Full Text] [Related]
26. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract][Full Text] [Related]
27. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
29.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
30. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
31. Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers.
Sulaiman R; De P; Aske JC; Lin X; Dale A; Koirala N; Gaster K; Espaillat LR; Starks D; Dey N
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446260
[TBL] [Abstract][Full Text] [Related]
32. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
34. Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.
Hoskins EL; Samorodnitsky E; Wing MR; Reeser JW; Hopkins JF; Murugesan K; Kuang Z; Vella R; Stein L; Risch Z; Yu L; Adebola S; Paruchuri A; Carpten J; Chahoud J; Edge S; Kolesar J; McCarter M; Nepple KG; Reilley M; Scaife C; Tripathi A; Single N; Huang RSP; Albacker LA; Roychowdhury S
JCO Precis Oncol; 2023 Jan; 7():e2200300. PubMed ID: 36623238
[TBL] [Abstract][Full Text] [Related]
35. Correlation between PD-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
[TBL] [Abstract][Full Text] [Related]
36. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
38. Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
Zheng S; Ma J; Li J; Pang X; Ma M; Ma Z; Cui W
Hum Immunol; 2023 Oct; 84(10):551-560. PubMed ID: 37481380
[TBL] [Abstract][Full Text] [Related]
39. [Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].
Fu YL; Xue XM; Shen GH; Yuan LJ; Zheng B; Zhang HF; Qiu T; Huang WT
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):751-755. PubMed ID: 34405609
[No Abstract] [Full Text] [Related]
40. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features.
Takamatsu D; Kiyozawa D; Kohashi K; Kinoshita F; Toda Y; Ishihara S; Eto M; Oda Y
Pathol Res Pract; 2023 Apr; 244():154423. PubMed ID: 36989848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]